Pharma IQ Editor
Pharma IQ speaks to Dr Samantha Carmichael, Lead Pharmacist Clinical Trials of NHS Greater Glasgow & Clyde and Mandy Wan, Lead Paediatric Research Pharmacist, Evelina London Children’s Hospital in regards to the growing culture of site centricity in today’s clinical trials.
Earlier this month, Industry members gathered to tackle challenges and contribute to the discussion surrounding cell and gene therapies and their manufacture.
The first respiratory biomedicine from AstraZeneca received primary and key secondary endpoints in the third phase of clinical trials. The therapy, Benralizumab, when combined with standard medicine was seen to significantly reduce severity of asthma symptoms and enhanced lung function with individuals which harbour an eosinophilic phenotype.
The packaging, labelling and artwork division of the pharma market faces pressure from a range of directions. Varying country requirements, refreshed regulations, controlling the demanding overheads and arguably the one of the most costly pressures is the combat against pharmaceutical inappropriate use by patients. Pharmaceuticals taken... Read more
Pharma IQ takes a look at some of the industry’s most prestigious movers and shakers causing ripples in the market over the last few months.
Pharma IQ zooms through the latest predicted trends for the compound and biological sample management industries. The video explores investment levels, team sizes, top challenges and areas for growth.
The global healthcare CRO market has been forecasted to reach US$45 billion by 2022, according to new research. (2) In terms of market shares, the geos rank as follows: North America, Europe, Asia Pacific, with China and India expected to see dramatic growth within this period. In light of this growing market, the Pharma IQ community was invited... Read more
On the route to creating new therapeutics for patients, pharma firms require access a range of diverse biological samples. However, one challenge for the market is locating collaborations that will provide a channel to diverse and high quality samples. This is mirrored by the intentions of both public biobanks and academic or hospital biobanks... Read more
In 2015, the pharma and biotech industry was diagnosed with what was coined as merger fever. Industry analysts state that the first half of 2015 soared past 2014’s grand total of $162 billion, with the total value of pharma M&As in the first two quarters of 2015 sitting at $221 billion.